Cytology
A groundbreaking phase I/II clinical trial is underway to treat chronic lymphocytic leukemia (CLL) using an innovative immunotherapeutic approach. The trial, sponsored by the Center for Cell and Gene Therapy at Baylor College of Medicine and The Methodist Hospital, utilizes MaxCyte's MaxCyte GT cell loading system to
Cytology
A new study from Canada has found that human herpesvirus 8 (HHV-8) specific antibodies are detectable in hematopoietic stem cell transplant recipients using a peptide-based enzyme immunoassay. The study, published in the Journal of Clinical Microbiology, evaluated the seroprevalence of HHV-8 in 42 allogeneic SCT recipients from Canada and found
Cytology
Children who require intensive care after undergoing hematopoietic stem cell transplant (HSCT) face a high risk of mortality, according to a study published in Hematological Oncology. Researchers analyzed the outcomes of 125 pediatric HSCT recipients and identified several prognostic factors that predict survival and death. The study found that patients
Cytology
Researchers have developed an interleukin 12-engineered allogeneic cell vaccine that exhibits a remarkable 80% efficacy in preventing HER-2/neu transgenic breast cancer in mice. This breakthrough study, published in the journal Cancer Research, highlights the potential of immunotherapy in cancer prevention. The vaccine, engineered to release interleukin (IL)-12, has
Cytology
Researchers in China have successfully used a TCR DNA vaccine to induce a humoral immunoreaction in mice with T cell lymphoma. The study, published in Vaccine, found that mice vaccinated with the TCR DNA vaccine produced antibodies against the beta chain of T cell lymphoma, with the highest antibody titers
Cytology
Scientific surveys conducted by Canadian researchers have identified significant variability in current practices relating to cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada. The Centers for Disease Control (CDC) guidelines for prevention and management of cytomegalovirus disease after hematopoietic stem cell transplantation were compared to current practices
Cytology
A recent study from the United States has found a correlation between the dose of hematopoietic stem cells and the speed of immune reconstitution after stem cell transplant. The research, published in Blood, used a congenic transplantation model to test the effect of different stem cell doses on immune recovery.
Cytology
Researchers at St. Bartholomew's Hospital in London have investigated the effectiveness of a new chemotherapy regimen for advanced ovarian cancer. The treatment involves a combination of gemcitabine, carboplatin, and paclitaxel, along with peripheral blood progenitor cell support, administered every 10 days for six cycles. This approach has shown
Cytology
Bone marrow cells have long been investigated for their potential to regenerate damaged heart tissue. Recent studies have suggested that these cells might possess a broader differentiation potential than previously thought. However, the exact identity, longevity, and fate of these cells in infarcted myocardium have yet to be fully understood.
Cytology
Children undergoing hematopoietic stem cell transplantation (SCT) after busulphan/cyclophosphamide-based conditioning regimens may experience unexplained disturbances of growth, particularly if they have not received gonadotoxic therapy prior to the treatment. The growth impairment may be attributed to insufficient growth hormone secretion. Additionally, thyroid function may be disrupted in some patients,
Cytology
In the wake of Ronald Reagan's passing due to complications of Alzheimer's disease, the question of using embryos for stem cell research remains a contentious issue. President Bush has reaffirmed his stance against using embryos for stem cell research, despite rising calls for relaxation of federal
Cytology
Cellerant Therapeutics, Inc., a developer of therapies based on hematopoietic stem cells, has made two significant appointments to its research team, positioning the company for further advancements in cell products and cell-based therapies. Timothy C. Fong, PhD, has been named Vice President of Research, bringing expertise in hematology, oncology, and
